BTK inhibitors are a possible emerging therapeutic target for gastric cancer DOI Creative Commons
José Darío Portillo‐Miño,

Jhon Jairo Calderon,

Arnoldo Riquelme

et al.

Deleted Journal, Journal Year: 2025, Volume and Issue: 33(1), P. 200935 - 200935

Published: Feb. 3, 2025

Language: Английский

Chemotherapy Options for Locally Advanced Gastric Cancer: A Review DOI Open Access
Yuliya Semenova, Altay Kerimkulov, Talgat Uskenbayev

et al.

Cancers, Journal Year: 2025, Volume and Issue: 17(5), P. 809 - 809

Published: Feb. 26, 2025

Cancers represent a significant global health burden, affecting millions of individuals each year [...].

Language: Английский

Citations

0

From Bench to Bedside: Transforming Cancer Therapy with Protease Inhibitors DOI Open Access
Alireza Shoari

Targets, Journal Year: 2025, Volume and Issue: 3(1), P. 8 - 8

Published: March 3, 2025

Proteases play a pivotal role in cancer progression, facilitating processes such as extracellular matrix degradation, angiogenesis, and metastasis. Consequently, protease inhibitors have emerged promising therapeutic agents oncology. This review provides comprehensive overview of the mechanisms by which modulate biology, categorizing their target classes, including metalloproteinases, cysteine proteases, serine proteases. We discuss potential both synthetic natural inhibitors, highlighting applications preclinical clinical settings. Furthermore, challenges specificity, toxicity, resistance are addressed, alongside strategies to overcome these limitations through innovative drug designs combination therapies. The future treatment lies precision medicine, leveraging proteomic profiling tailor therapies individual tumors. underscores importance ongoing research development novel approaches harness effectively for management.

Language: Английский

Citations

0

Applications and challenges of immunotherapy in the management of gastric adenocarcinoma: current status and future perspectives DOI Creative Commons
Zhiyao Chen,

Yunbin Ma,

Jianan Chen

et al.

World Journal of Surgical Oncology, Journal Year: 2025, Volume and Issue: 23(1)

Published: March 19, 2025

Gastric adenocarcinoma (GAC) remains a significant global public health challenge, characterized by high incidence and mortality rates. Progress in tumor immunology has introduced immune checkpoint inhibitors (ICIs) targeting the programmed cell death-1 (PD-1)/programmed death-ligand 1 (PD-L1) cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) pathways, demonstrating substantial potential GAC therapy. Clinical research indicates that ICIs, particularly when combined with chemotherapy or targeted therapies, significantly enhance treatment efficacy advanced specific molecular subtypes, including microsatellite instability-high (MSI-H) human epidermal growth factor receptor 2 (HER2)-positive patients. However, immunotherapy is also associated range of immune-related adverse events (irAEs), necessitating effective management strategies to ensure safety maintain patients' quality life. Future studies should focus on identifying new therapeutic targets, optimizing patient selection, developing personalized approaches further improve GAC.

Language: Английский

Citations

0

Portrayal of the Complex Molecular Landscape of Multidrug Resistance in Gastric Cancer: Unveiling the Potential Targets DOI

S. Biswas,

Riya Kanodia,

Suman Seervi

et al.

Experimental Cell Research, Journal Year: 2025, Volume and Issue: unknown, P. 114580 - 114580

Published: April 1, 2025

Language: Английский

Citations

0

Design, optimization, and ADMET evaluation of S11a-0000168202: A promising LIMK1 inhibitor for gastric cancer treatment DOI Creative Commons
Guojun Li, Jionghuang Chen, Rui Chen

et al.

PLoS ONE, Journal Year: 2025, Volume and Issue: 20(5), P. e0323699 - e0323699

Published: May 14, 2025

This study focuses on the development and optimization of S11a-0000168202, a novel LIMK1 inhibitor with potential therapeutic applications in gastric cancer. Through scaffold hopping structural modification HIT100844099, S11a-0000168202 demonstrated enhanced binding stability stronger interactions key residues, including GLU-414, ILE-416, HIS-464. Molecular dynamics simulations MMGBSA analyses confirmed compound’s stability, while ADMET evaluation revealed favorable properties such as moderate lipophilicity, good human intestinal absorption, low P-glycoprotein inhibition. Despite promising computational results, lack experimental validation remains limitation. Future studies should focus vitro vivo testing to confirm S11a-0000168202’s efficacy, pharmacokinetics, safety. compound holds significant agent for LIMK1-targeted cancer treatment.

Language: Английский

Citations

0

BTK inhibitors are a possible emerging therapeutic target for gastric cancer DOI Creative Commons
José Darío Portillo‐Miño,

Jhon Jairo Calderon,

Arnoldo Riquelme

et al.

Deleted Journal, Journal Year: 2025, Volume and Issue: 33(1), P. 200935 - 200935

Published: Feb. 3, 2025

Language: Английский

Citations

0